Live feed07:00:00·262dPRReleasevia QuantisnowFDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish FacilityByQuantisnow·Wall Street's wire, on your screen.SRRK· Scholar Rock Holding CorporationHealth Care